Metabolic syndrome and cognitive disorders: Is the sum greater than its parts?

Alzheimer Disease and Associated Disorders

Volumn 21, Issue 2, 2007, Pages 167-171

  Yaffe, Kristine ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cognition; Dementia; Inflammation; Insulin resistance; Metabolic syndrome

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ANTIDIABETIC AGENT; C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN;

ABDOMINAL OBESITY; AGING; ALZHEIMER DISEASE; BODY COMPOSITION; CARDIOVASCULAR RISK; COGNITIVE DEFECT; DEMENTIA; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; ETHNIC DIFFERENCE; GLUCOSE BLOOD LEVEL; HISPANIC; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; MENTAL HEALTH; METABOLIC SYNDROME X; MICROANGIOPATHY; MULTIINFARCT DEMENTIA; OBESITY; PREVALENCE; PRIORITY JOURNAL; REVIEW;

AGING; COGNITION DISORDERS; HUMANS; METABOLIC SYNDROME X; RISK FACTORS;

EID: 34249948187     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e318065bfd6     Document Type: Review

References (40)

1. Ott A, Breteler MM, van Harskamp F, et al. Incidence and risk of dementia. The Rotterdam Study. Am J Epidemiol. 1998;147:574-580.
2. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88:1337-1342.
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). JAMA. 2001;285:2486-2497.
4. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359.
5. Launer LJ, Masaki K, Petrovitch H, et al. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA. 1995;274:1846-1851.
6. Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 2005;4:8487-8499.
7. Kanaya AM, Barrett-Connor E, Gildengorin G, et al. Change in cognitive function by glucose tolerance status in older adults: a 4-year prospective study of the Rancho Bernardo study cohort. Arch Intern Med. 2004;164:1327-1333.
8. Grodstein F, Chen J, Wilson RS, et al. Type 2 diabetes and cognitive function in community-dwelling elderly women. Diabetes Care. 2001;24:1060-1065.
9. Gregg EW, Yaffe K, Cauley JA, et al. Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group. Arch Intern Med. 2000;160:174-180.
10. Yaffe K, Blackwell T, Kanaya AM, et al. Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology. 2004;63:658-663.
11. Yaffe K, Barrett-Connor E, Lin F, et al. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol. 2002;59:378-384.
12. Moroney JT, Tang MX, Berglund L, et al. Low-density lipoprotein cholesterol and the risk of dementia with stroke. JAMA. 1999;282: 254-260.
13. Gustafson D, Rothenberg E, Blennow K, et al. An 18-year followup of overweight and risk of Alzheimer disease. Arch Intern Med. 2003;163:1524-1528.
14. Whitmer RA, Gunderson EP, Barrett-Connor E, et al. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ. 2005;330:1360.
15. Yaffe K, Kanaya A, Lindquist K, et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA. 2004;292: 2237-2242.
16. Census US. National Population Projections. Washington DC, US: Government Printing Office; 2000.
17. Haan MN, Mungas DM, Gonzalez HM, et al. Prevalence of dementia in older Latinos: the influence of type 2 diabetes mellitus, stroke and genetic factors. J Am Geriatr Soc. 2003;51:169-177.
18. Yaffe K, Haan MN, Blackwell T, et al. Metabolic syndrome and cognitive decline in elderly latinos: findings from the SALSA Study. J Am Geriatr Soc. In press.
19. Dik MG, Penninx B, Comijs HC, et al. The metabolic syndrome, inflammation, and cognitive decline. Alzheimer's Dementia. 2006; 2(suppl 1):S414.
20. Launer LJ. Demonstrating the case that AD is a vascular disease: epidemiologic evidence. Ageing Res Rev. 2002;1:61-77.
21. Luchsinger JA, Tang MX, Stern Y, et al. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol. 2001;154:635-641.
22. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327-334.
23. Barzilay JI, Abraham L, Heckbert SR, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes. 2001;50:2384-2389.
24. McGeer EG, McGeer PL. Brain inflammation in Alzheimer disease and the therapeutic implications. Curr Pharm Des. 1999;5:821-836.
25. Yaffe K, Lindquist K, Penninx BW, et al. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology. 2003;61:76-80.
26. Dandona P, Aljada A, Chaudhuri A, et al. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005;111:1448-1454.
27. Haffner SM. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol. 2006;97:3A-11A.
28. Grundy SM. Inflammation, hypertension, and the metabolic syndrome. JAMA. 2003;290:3000-3002.
29. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107:391-397.
30. Knopman D, Boland LL, Mosley T, et al. Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology. 2001;56:42-48.
31. Luchsinger JA, Tang MX, Shea S, et al. Hyperinsulinemia and risk of Alzheimer disease. Neurology. 2004;63:1187-1192.
32. Yaffe K, Blackwell T, Whitmer RA, et al. Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in older women. J Nutr Health Aging. 2006;10:293-295.
33. Farris W, Mansourian S, Chang Y, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the betaamyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A. 2003;100:4162-4167.
34. Kulstad JJ, Green PS, Cook DG, et al. Differential modulation of plasma beta-amyloid by insulin in patients with Alzheimer disease. Neurology. 2006;66:1506-1510.
35. Jagust W, Harvey D, Mungas D, et al. Central obesity and the aging brain. Arch Neurol. 2005;62:1545-1548.
36. Benoit SC, Clegg DJ, Seeley RJ, et al. Insulin and leptin as adiposity signals. Recent Prog Horm Res. 2004;59:267-285.
37. Harvey J. Leptin: a multifaceted hormone in the central nervous system. Mol Neurobiol. 2003;28:245-258.
38. Fewlass DC, Noboa K, Pi-Sunyer FX, et al. Obesity-related leptin regulates Alzheimer's Abeta. Faseb J. 2004;18:1870-1878.
39. Zamboni M, Zoico E, Fantin F, et al. Relation between leptin and the metabolic syndrome in elderly women. J Gerontol A Biol Sci Med Sci. 2004;59:396-400.
40. Holden KF, Lindquist K, Rosano C, et al. Low Serum Leptin is Associated With Poor Cognitive Performance in the Elderly. San Diego, CA: American Academy of Neurology; 2006.